Fibrinogen concentrate for acquired hypofibrinogenaemic states

Transfusion Medicine

Volumn 18, Issue 3, 2008, Pages 151-157

  Weinkove, R ^a   Rangarajan, S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Disseminated intravascular coagulation; Fibrinogen; Fibrinogen concentrate; Haemocomplettan; Hypofibrinogenaemia

Indexed keywords

FIBRINOGEN; HAEMOCOMPLETTAN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CRYOPRECIPITATE; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEART SURGERY; HOSPITAL PATIENT; HUMAN; HYPOFIBRINOGENEMIA; HYPOTENSION; LIVER FAILURE; MORTALITY; SOLUTIO PLACENTAE; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AFIBRINOGENEMIA; AGED; FIBRINOGEN; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 45349083292     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2008.00854.x     Document Type: Article

References (20)

1. Blome, M., Isgro, F., Kiessling, A.H., Skuras, J., Haubelt, H., Hellstern, P. Saggau, W. (2005) Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thrombosis and Haemostasis, 93, 1101 1107.
2. Bonik, K., Rode, M.D. Broder, M. (1996) Therapie von Fibrinogenmangelzuständen. Hämostaseologie, 16, 194 199.
3. Burthem, J. Roberts, D.J. (2003) The pathophysiology of variant Creutzfeldt-Jacob disease: the hypotheses behind concerns for blood components and products. British Journal of Haematology, 122, 3 9.
4. Farriols Danés, A., Gallur Cuenca, L., Rodriguez Bueno, S., Mendarte Barrenechea, L. Bruno Montoro Ronsano, J. (2008) Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sanguinis, 94, 221 226.
5. Foster, P.R. (1999) Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfusion Medicine, 9, 3 14.
6. Foster, P.R., Welch, A.G., McLean, C., Griffin, B.D., Hardy, J.C., Bartley, A., MacDonald, S. Bailey, A.C. (2000) Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sanguinis, 78, 86 95.
7. Gibson, B.E., Todd, A., Roberts, I. et al 2004) Transfusion guidelines for neonates and older children. British Journal of Haematology, 124, 433 453.
8. Goodnight, S.H. Hathaway, W.E. (2000) Abnormalities of fibrinogen. In : Disorders of Hemostasis and Thrombosis: A Clinical Guide (2nd edn eds Goodnight, S.H Hathaway, W.E 18, 175 183. McGraw-Hill, New York.
9. Heindl, B., DeLorenzo, C. Spannagl, M. (2005) Hochdosierte Fibrinogengabe zur Akuttherapie von Gerinnungsstörungen bei perioperativer Massivtransfusion. Anaesthesist, 54, 787 790.
10. Kreuz, W., Meili, E., Peter-Salonen, K., Dobrkovská, A., Devay, J., Haertel, S., Krzensk, U. Egbring, R. (2005a) Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfusion and Apheresis Science, 32, 239 246.
11. Kreuz, W., Meili, E., Peter-Salonen, K., Haertel, S., Devay, J., Krzensk, U. Egbring, R. (2005b) Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfusion and Apheresis Science, 32, 247 253.
12. Lee, D.C., Stenland, C.J., Miller, J.L.C. et al 2001) A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion, 41, 449 455.
13. Mangano, D.T., Tudor, I.C. Dietzel, C. (2006) The risk associated with aprotinin in cardiac surgery. New England Journal of Medicine, 354, 353 365.
14. National Blood Service (2005) Guidelines for the Blood Transfusion Services in the UK (7th edn). The Stationery Office, London.
15. O'Shaughnessy, D.F., Atterbury, C., Bolton-Maggs, P., Murphy, M., Thomas, D., Yates, S. Williamson, L.M. (2004) Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Journal of Haematology, 126, 11 28.
16. Pereira, A. (2007) Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica, 92, 846 849.
17. Spero, J.A., Lewis, J.H. Hasiba, U. (1980) Disseminated intravascular coagulation. Findings in 346 patients. Thrombosis and Haemostasis, 43, 28 33.
18. United Kingdom Haemophilia Centre Doctors' Organisation (2003) Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia, 9, 1 23.
19. Violi, F., Ferro, D., Basili, S., Quintarelli, C., Musca, A., Cordova, C. Balsano, F. (1993) Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology, 17, 78 83.
20. ® P 1g / 2g Company Core Package Insert. ZLB Behring, Marburg.